Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR

Featuring perspectives from Dr John V Heymach and Dr Maurice Pérol, including the following topics:

Introduction: Relative Impact of Targeted Treatment (00:00)
HER2 Alterations (8:04)
KRAS Mutations (24:25)
MET Overexpression (30:34)
ALK Fusions (32:34)
ROS1 Fusions (42:36)
RET Fusions (52:00)